Drug profile · INN
elotuzumab
EMPLICITI
elotuzumab (EMPLICITI) is a slam family member 7 inhibitor. Associated with Bristol-Myers Squibb Australia Pty Ltd. Route of administration: injection. Current US regulatory status: approved.
Drug details — elotuzumab
- US status
- approved
- Class
- Antineoplastic and immunomodulating agents (L01)
- Route
- INJECTION
- Patents
- 0
- Programs
- 10
- Data quality
- 0.84
Quick answer
elotuzumab (EMPLICITI) is a slam family member 7 inhibitor. Associated with Bristol-Myers Squibb Australia Pty Ltd. Route of administration: injection. Current US regulatory status: approved.
Key facts
Mechanism of action
SLAM family member 7 inhibitor
Primary target: SLAM family member 7
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
| EMA | approved | — |
| TGA | approved | — |
| PMDA | approved | — |
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is elotuzumab?
elotuzumab (EMPLICITI) is a slam family member 7 inhibitor. Associated with Bristol-Myers Squibb Australia Pty Ltd. Route of administration: injection. Current US regulatory status: approved.
What is the brand name for elotuzumab?
EMPLICITI is a marketed brand name for elotuzumab. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of elotuzumab?
elotuzumab has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.